XOMA Corp was incorporated in Delaware on 1981 and became a Bermuda-exempted company in December 1998. The Company is a biotechnology company, which is engaged in the discovery, development and manufacture of therapeutic antibodies and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company builds a product pipeline that includes multiple proprietary and collaborative development programs. Its proprietary preclinical pipeline includes classes of antibodies that activate, sensitize, or deactivate the insulin receptor in vivo, that have been named as XMet. This portfolio of antibodies represents potential new therapeutic approaches to the treatment of diabetes and several diseases that involve insulin, which it believe may be orphan drug opportunities. Its main product candidate is XOMA 052, a potent monoclonal antibody with the potential to improve the treatment of patients with a number of diseases in which inflammation is either the cause or plays a considerable role. The company receives royalties on approved products, RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis, LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration, and the Company no longer receives royalties on sales of CIMZIA. XOMA has granted more than 60 licenses to biotechnology and pharmaceutical companies to use the Company's patented and proprietary technologies relating to bacterial expression of recombinant pharmaceutical products.